Status:
TERMINATED
A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This study aim was to determine the safety and efficacy of R1507 in combination with letrozole in patients with advanced breast cancer. In the first part of the study a cohort of patients with advance...
Eligibility Criteria
Inclusion
- postmenopausal female patients;
- stage IV or locally advanced breast cancer;
- measurable disease;
- letrozole failure (Part 2);
- Eastern Cooperative Oncology Group (ECOG) performance status \<=2.
Exclusion
- previous chemotherapy for metastatic breast cancer;
- concurrent antibody or immunotherapy for advanced disease, within 4 weeks prior to receipt of study drug;
- history of primary malignancy in 5 years prior to study, excluding adequately treated basal or squamous cell cancer of skin, or cancer in situ of cervix;
- concurrent radiotherapy, or radiotherapy within 28 days prior to receipt of study drug.
Key Trial Info
Start Date :
January 28 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 3 2010
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00796107
Start Date
January 28 2009
End Date
March 3 2010
Last Update
November 13 2020
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35294-3300
2
Washington D.C., District of Columbia, United States, 20007
3
Miami, Florida, United States, 33136
4
Atlanta, Georgia, United States, 30322